secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0001193125-25-002153
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics CEO J. Scott Wolchko retires; Bahram Valamehr appointed successor; advisory agreement signed
--------------------------------------------------------------------------------

- J. Scott Wolchko retired as President, CEO, and CFO effective Dec 31, 2024; resignation not due to any policy disagreement.
- Bahram Valamehr, Ph.D., MBA succeeded as President, CEO, and subsidiary roles effective Jan 1, 2025.
- Wolchko entered 12-month advisory agreement with $56,250 monthly cash compensation and continued equity vesting through Dec 31, 2025.
- Wolchko's vested options may be exercised until Dec 31, 2026; equity awards accelerate if agreement terminated early by company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000119312525002153/0001193125-25-002153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000119312525002153/d900848d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-002153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer